New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or ...

Data taken from [20]. Table 2. Hormone therapy: degree of regression in adenocarcinoma following neoadjuvant and duration of therapy †. Biopsy Gleason score Degree of regression according to the ...

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient ...

Sep. 4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay ...

Amid rumors about Israeli PM Benjamin Netanyahu's prostate surgery, medical experts raise key questions about the procedure's ...

Treatment options include active surveillance (monitoring the cancer closely and opting for treatment if it progresses), radiation therapy, hormone therapy and chemotherapy. Surgery, specifically ...

Since it’s likely their patients will pursue complementary therapies during the course of their treatment ... prostate cancer progression, including biochemical recurrence, metastasis, hormone ...